vs

Side-by-side financial comparison of i3 Verticals, Inc. (IIIV) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

i3 Verticals, Inc. is the larger business by last-quarter revenue ($52.7M vs $28.8M, roughly 1.8× X4 Pharmaceuticals, Inc). X4 Pharmaceuticals, Inc runs the higher net margin — 1.0% vs 0.9%, a 0.1% gap on every dollar of revenue.

The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

IIIV vs XFOR — Head-to-Head

Bigger by revenue
IIIV
IIIV
1.8× larger
IIIV
$52.7M
$28.8M
XFOR
Higher net margin
XFOR
XFOR
0.1% more per $
XFOR
1.0%
0.9%
IIIV

Income Statement — Q1 FY2026 vs Q1 FY2025

Metric
IIIV
IIIV
XFOR
XFOR
Revenue
$52.7M
$28.8M
Net Profit
$484.0K
$282.0K
Gross Margin
83.6%
Operating Margin
3.1%
-32.8%
Net Margin
0.9%
1.0%
Revenue YoY
-14.6%
Net Profit YoY
-76.5%
100.5%
EPS (diluted)
$0.02
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IIIV
IIIV
XFOR
XFOR
Q4 25
$52.7M
Q3 25
$46.0M
Q2 25
$51.9M
Q1 25
$63.1M
$28.8M
Q4 24
$52.2M
Q3 24
$32.0M
Q2 24
$46.2M
Q1 24
$58.0M
$0
Net Profit
IIIV
IIIV
XFOR
XFOR
Q4 25
$484.0K
Q3 25
$3.1M
Q2 25
$12.9M
Q1 25
$-154.0K
$282.0K
Q4 24
$2.1M
Q3 24
$117.9M
Q2 24
$-7.5M
Q1 24
$1.9M
$-51.8M
Gross Margin
IIIV
IIIV
XFOR
XFOR
Q4 25
Q3 25
Q2 25
Q1 25
83.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IIIV
IIIV
XFOR
XFOR
Q4 25
3.1%
Q3 25
3.2%
Q2 25
-9.3%
Q1 25
8.0%
-32.8%
Q4 24
3.9%
Q3 24
10.6%
Q2 24
-2.8%
Q1 24
3.4%
Net Margin
IIIV
IIIV
XFOR
XFOR
Q4 25
0.9%
Q3 25
6.7%
Q2 25
24.8%
Q1 25
-0.2%
1.0%
Q4 24
3.9%
Q3 24
368.2%
Q2 24
-16.3%
Q1 24
3.2%
EPS (diluted)
IIIV
IIIV
XFOR
XFOR
Q4 25
$0.02
Q3 25
$0.14
Q2 25
$0.50
Q1 25
$0.00
$0.04
Q4 24
$0.08
Q3 24
$4.93
Q2 24
$-0.32
Q1 24
$0.08
$-7.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IIIV
IIIV
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$37.5M
$40.3M
Total DebtLower is stronger
$75.0M
Stockholders' EquityBook value
$358.5M
$22.9M
Total Assets
$595.9M
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IIIV
IIIV
XFOR
XFOR
Q4 25
$37.5M
Q3 25
$66.7M
Q2 25
$55.5M
Q1 25
$7.7M
$40.3M
Q4 24
$85.6M
Q3 24
$86.5M
Q2 24
$9.7M
Q1 24
$3.1M
$60.5M
Total Debt
IIIV
IIIV
XFOR
XFOR
Q4 25
Q3 25
$0
Q2 25
$0
Q1 25
$12.0M
$75.0M
Q4 24
$26.2M
Q3 24
$26.2M
Q2 24
$374.1M
Q1 24
$369.6M
$55.0M
Stockholders' Equity
IIIV
IIIV
XFOR
XFOR
Q4 25
$358.5M
Q3 25
$389.6M
Q2 25
$383.3M
Q1 25
$385.2M
$22.9M
Q4 24
$375.0M
Q3 24
$379.7M
Q2 24
$249.7M
Q1 24
$249.3M
$1.0M
Total Assets
IIIV
IIIV
XFOR
XFOR
Q4 25
$595.9M
Q3 25
$638.4M
Q2 25
$623.3M
Q1 25
$646.4M
$130.0M
Q4 24
$726.2M
Q3 24
$730.7M
Q2 24
$861.7M
Q1 24
$625.8M
$112.2M
Debt / Equity
IIIV
IIIV
XFOR
XFOR
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.03×
3.27×
Q4 24
0.07×
Q3 24
0.07×
Q2 24
1.50×
Q1 24
1.48×
53.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IIIV
IIIV
XFOR
XFOR
Operating Cash FlowLast quarter
$14.1M
$-12.4M
Free Cash FlowOCF − Capex
$13.8M
FCF MarginFCF / Revenue
26.2%
Capex IntensityCapex / Revenue
0.6%
0.0%
Cash ConversionOCF / Net Profit
29.18×
-43.86×
TTM Free Cash FlowTrailing 4 quarters
$6.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IIIV
IIIV
XFOR
XFOR
Q4 25
$14.1M
Q3 25
$14.0M
Q2 25
$7.4M
Q1 25
$-27.1M
$-12.4M
Q4 24
$11.5M
Q3 24
$15.1M
Q2 24
$8.1M
Q1 24
$10.7M
$-33.6M
Free Cash Flow
IIIV
IIIV
XFOR
XFOR
Q4 25
$13.8M
Q3 25
$13.5M
Q2 25
$6.8M
Q1 25
$-27.6M
Q4 24
$11.0M
Q3 24
$14.6M
Q2 24
$7.2M
Q1 24
$9.9M
$-33.7M
FCF Margin
IIIV
IIIV
XFOR
XFOR
Q4 25
26.2%
Q3 25
29.5%
Q2 25
13.1%
Q1 25
-43.8%
Q4 24
21.1%
Q3 24
45.6%
Q2 24
15.6%
Q1 24
17.1%
Capex Intensity
IIIV
IIIV
XFOR
XFOR
Q4 25
0.6%
Q3 25
0.9%
Q2 25
1.0%
Q1 25
0.8%
0.0%
Q4 24
0.9%
Q3 24
1.7%
Q2 24
1.9%
Q1 24
1.4%
Cash Conversion
IIIV
IIIV
XFOR
XFOR
Q4 25
29.18×
Q3 25
4.52×
Q2 25
0.57×
Q1 25
-43.86×
Q4 24
5.59×
Q3 24
0.13×
Q2 24
Q1 24
5.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IIIV
IIIV

License And Service$35.7M68%
Proprietary Payments Revenue$14.5M27%
Other Revenue$2.5M5%

XFOR
XFOR

Segment breakdown not available.

Related Comparisons